Draft:Nutcracker Therapeutics
| Submission declined on 16 May 2024 by Grabup (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 10 May 2024 by Samoht27 (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
| |
| Submission declined on 29 December 2023 by Timtrent (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
| |
| Submission declined on 9 December 2023 by ToadetteEdit (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
| |
| Submission declined on 1 December 2023 by Stuartyeates (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
| |
Comment: To establish notability it needs multiple reliable independent sources with in-depth coverage of the subject not just passing mentions or interviews, sayings of the company, or connected person of the subject. GrabUp - Talk 17:12, 16 May 2024 (UTC)
- Comment: Appears to not be an improvement. Toadette (Happy holiday!) 06:05, 9 December 2023 (UTC)
- Comment: Press releases, patents and article by staffers are not independent. Stuartyeates (talk) 19:02, 1 December 2023 (UTC)
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology.[1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[2]. As of 2023, NTX-250 is in the preclinical stage of development.
References[edit]
- ^ Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696. PMC 9362478. PMID 35945442.
- ^ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.